Photo by paipai90 from unsplash
To report the first study of temelimab, a monoclonal antibody neutralizing the pathogenic human endogenous retrovirus type W envelope, in patients with type 1 diabetes (T1D). Click to show full abstract
To report the first study of temelimab, a monoclonal antibody neutralizing the pathogenic human endogenous retrovirus type W envelope, in patients with type 1 diabetes (T1D).
Keywords:
type envelope;
study temelimab;
human endogenous;
retrovirus type;
endogenous retrovirus;
monoclonal antibody
Journal Title: Diabetes
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!